Updates

CVS Group - CMD unveils new target to double EBITDA

December 2022

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

Following my main write-up last time at 1784p, the shares have rushed towards £20 as, with impeccable timing, CVS held a Capital Markets Day for investors and unveiled punchy new targets. Chief among these is to double EBITDA over the next five years, which implies an increase to £214m in FY’27 and compares with current forecasts from Berenberg for EBITDA to only reach £123m by FY’24 and £127m in ‘25. Significant investments are planned to improve practice margins through investment in facilities and equipment (£30-50m p.a) as well as potential investments in technology and three greenfield site openings this financial year - basically reiterating pretty much what I exclusively disclosed to subscribers last month. Medium term guidance is ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

Luceco

Sanderson

CVS Group (April 2024)

CVS Group (October 2023)

CVS Group (March 2023)

CVS Group (January 2023)

CVS Group - “Buy & build” vet practice group gearing up for new growth spurt (November 2022)

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X